201 related articles for article (PubMed ID: 28860832)
1. A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.
Taipale K; Winfree KB; Boye M; Basson M; Sleilaty G; Eaton J; Evans R; Chouaid C
Clinicoecon Outcomes Res; 2017; 9():505-518. PubMed ID: 28860832
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.
Kumar G; Woods B; Hess LM; Treat J; Boye ME; Bryden P; Winfree KB
Lung Cancer; 2015 Sep; 89(3):294-300. PubMed ID: 26122345
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
Permsuwan U; Thongprasert S; Sirichanchuen B
Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.
Chouaïd C; Crequit P; Borget I; Vergnenegre A
Clinicoecon Outcomes Res; 2015; 7():9-15. PubMed ID: 25548525
[TBL] [Abstract][Full Text] [Related]
10. Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.
Shi Y; Qian D; Li Y; Chen W; Bo M; Zhang M; Shi J; Jia B; Dai Y; Li G
Transl Cancer Res; 2023 Apr; 12(4):928-938. PubMed ID: 37180653
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
Porte F; Granghaud A; Chang J; Kearney M; Morel A; Plessala I; Cawston H; Roiz J; Xiao Y; Solbes MN; Lambert P; Ravaud A; Loriot Y; Thiery-Vuillemin A; Lévy P
PLoS One; 2024; 19(5):e0302548. PubMed ID: 38728337
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
13. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y; Bagust A; Dickson R; Dodd S; Green J; Haycox A; Hill R; McLeod C; Walley T
Health Technol Assess; 2007 Jan; 11(1):1-90. PubMed ID: 17181984
[TBL] [Abstract][Full Text] [Related]
15. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China.
Shi Q; Hu S; Furnback WE; Guzauskas GF; Shen J; Wang BC
Clinicoecon Outcomes Res; 2017; 9():99-106. PubMed ID: 28210100
[TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
18. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Luo X; Zhou Z; Zeng X; Liu Q
Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
[No Abstract] [Full Text] [Related]
19. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
Shi Y; Pei R; Liu S
Front Oncol; 2022; 12():833773. PubMed ID: 36324594
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]